LPL Financial LLC Has $452,000 Position in Xencor, Inc. (NASDAQ:XNCR)

LPL Financial LLC lifted its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 12.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,680 shares of the biopharmaceutical company’s stock after purchasing an additional 2,113 shares during the period. LPL Financial LLC’s holdings in Xencor were worth $452,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in XNCR. Barclays PLC lifted its stake in Xencor by 100.7% in the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company’s stock valued at $3,128,000 after buying an additional 78,066 shares during the period. Geode Capital Management LLC lifted its position in shares of Xencor by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,455,350 shares of the biopharmaceutical company’s stock valued at $29,273,000 after acquiring an additional 17,658 shares during the period. Principal Financial Group Inc. boosted its stake in Xencor by 16.5% during the fourth quarter. Principal Financial Group Inc. now owns 340,145 shares of the biopharmaceutical company’s stock worth $7,817,000 after acquiring an additional 48,229 shares in the last quarter. Amundi grew its holdings in Xencor by 225.0% in the fourth quarter. Amundi now owns 35,380 shares of the biopharmaceutical company’s stock worth $829,000 after purchasing an additional 24,494 shares during the period. Finally, Sanctuary Advisors LLC increased its stake in Xencor by 5.3% in the fourth quarter. Sanctuary Advisors LLC now owns 28,263 shares of the biopharmaceutical company’s stock valued at $649,000 after purchasing an additional 1,432 shares in the last quarter.

Xencor Stock Performance

Shares of XNCR stock opened at $10.51 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The firm has a 50-day moving average of $11.77 and a 200-day moving average of $18.43. Xencor, Inc. has a one year low of $7.16 and a one year high of $27.24. The company has a market cap of $740.56 million, a P/E ratio of -3.28 and a beta of 0.90.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.19. The business had revenue of $52.79 million for the quarter, compared to analysts’ expectations of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. Equities research analysts forecast that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. William Blair started coverage on shares of Xencor in a research report on Monday, April 21st. They set an “outperform” rating on the stock. Wells Fargo & Company lowered their target price on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Finally, StockNews.com downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.86.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.